Biocon reports 13% profit rise, files biosimilar Herceptin in India
This article was originally published in Scrip
Executive Summary
India's largest biotechnology firm, Biocon, has reported a 13% increase in net profit to INR1.02bn ($16.6m) for the second quarter ended 30 September, backed by steady growth in its mainstay biopharmaceutical business and a strong showing for its research services unit. Revenues increased by 17% to INR7.53bn.